Publications by authors named "J C Baranda"
Introduction: Existing literature suggests that women are significantly underrepresented in the field of hematology-oncology. Women make up 35.6% of hematologists and data on females as site investigators for pivotal trials and authors in publications of pivotal trials in hematologic malignancies, specifically in the novel niche of Chimeric antigen receptor T cell (CAR-T), is sparse.
View Article and Find Full Text PDFArticle Synopsis
- SAR439459 (SAR'459) is a new monoclonal antibody designed to improve the effects of immune checkpoint inhibitors, and it was tested for safety and effectiveness in patients with advanced solid tumors.* -
- The study, which consisted of multiple phases, revealed that the maximum dose tolerated was never reached, but adverse effects included significant events such as hemorrhagic issues and skin neoplasms.* -
- Ultimately, the combination therapy showed limited preliminary antitumor activity, which led to the decision to discontinue the study due to unclear effectiveness.*
Cancer vaccines strive to induce robust, antigen-targeted, T-cell-mediated immune responses but have struggled to produce meaningful regression in solid tumors. An autologous cell vaccine, SQZ-PBMC-HPV, was developed by SQZ Biotechnologies using microfluidic squeezing technology to load PBMCs with HPV16 E6 and E7 antigens in HLA-A*02+ patients. The SQZ-PBMC-HPV-101 Phase 1 trial (NCT04084951) enrolled patients with incurable HPV16+ cancers.
View Article and Find Full Text PDFArticle Synopsis
- - The CAMILLA trial evaluated the combination of cabozantinib and durvalumab in 29 patients with advanced gastrointestinal cancers that did not respond to chemotherapy, all of whom had confirmed pMMR/MSS tumors.
- - The study found an overall response rate (ORR) of 27.6%, with 44.83% of patients showing a 4-month progression-free survival (PFS) rate and a median overall survival (OS) of 9.1 months; 39% of patients experienced grade ≥3 treatment-related adverse events (TRAE).
- - A post-hoc analysis indicated that patients with RAS wild-type tumors had a better ORR of 50%, and the study also identified
There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response to treatment more efficiently than imaging. We report an innovative approach that will generate renewed interest in using circulating tumor cells (CTCs) to monitor treatment efficacy, which, in this case, used PDAC patients receiving an exploratory new therapy, poly ADP-ribose polymerase inhibitor (PARPi)-niraparib-as a case study. CTCs were enumerated from whole blood using a microfluidic approach that affinity captures epithelial and mesenchymal CTCs using anti-EpCAM and anti-FAPα monoclonal antibodies, respectively.
View Article and Find Full Text PDF